IP Library › Granted Patent US 9,637,488
Granted Patent B2
US 9,637,488 · App. 14/998,635 · Granted May 2, 2017

Heterocyclic compounds as inhibitors of class I PI3KS

Inventor: Fuqiang Ruan (Bellevue, WA)
C07D473/34A61K31/506A61K31/52A61K31/5377A61K31/55A61K45/06C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,488
App. No.
14/998,635
Granted
May 2, 2017
Kind
B2
Abstract

The present application discloses a novel class of heterocycles as class I PI3Ks inhibitors. The compounds claimed herein could be used alone or in combination therapies for the treatment of a wide range of disorders such as autoimmune, inflammatory and allergic diseases, asthma, COPD, parasitic infections, diabetes, and cancer.

Claims (18)

1. A compound having the structure of formula (I):

wherein:

X is selected from: —CH 2 CH 2 —, —CH═CHCH 2 — or —CH 2 CH 2 CH 2 —;

Z is hydrogen;

R 1 is selected from: phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, piperidine, morpholine, or phenyl which is substituted by at least one substituent selected from: deuterium, —CH 3 , —OCH 3 , —OCF 3 , or —F;

R 2 and R 3 are independently selected from: hydrogen, deuterium, C 1 -C 6 alkyl, or halogen;

Y is selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 and R 3 are independently selected from: hydrogen, deuterium, —F, —Cl, or —CH 3 .

3. A compound having the structure of formula (II):

wherein:

X is —CH 2 CH 2 —;

Z is hydrogen;

R 1 is selected from: phenyl, pyridyl, or morpholine;

R 2 and R 3 are independently selected from: hydrogen, deuterium, —F, —Cl, or —CH 3 ;

Y is selected from:

or a pharmaceutically acceptable salt thereof.

4. The compound of claims 1 , 2 or 3 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

Continuity (2)
Provisional Application 62125731 · Jan 29, 2015
Related Publication 20160222012A1 · Aug 4, 2016